© 1999 by Oxford University Press
Journal of the National Cancer Institute, Vol. 91, No. 10, 839-846,
May 19, 1999
© 1999 Oxford University Press
Impact of the Treating Institution on Survival of Patients With "Poor-Prognosis" Metastatic Nonseminoma
Affiliations of authors: L. Collette, R. J. Sylvester, N. Neymark, European Organization for Research and Treatment of Cancer (EORTC) Data Center, Brussels, Belgium; S. P. Stenning, E. Lallemand, Medical Research Council (MRC) Cancer Trials Office, Cambridge, U.K.; S. D. Fossa, The Radium Hospital, Oslo, Norway; G. M. Mead, Royal South Hants Hospital, Southampton, U.K.; R. de Wit, Rotterdam Cancer Institute and University Hospital, The Netherlands; P. H. M. de Mulder, Sint Radboud University Hospital, Nijmegen, The Netherlands; S. B. Kaye, Western Infirmary, Glasgow, U.K.
Correspondence to: Laurence Collette, M.Sc., EORTC Data Center, Avenue Mounier 83/11, 1200 Brussels, Belgium (e-mail: lco{at}eortc.be).
BACKGROUND: Because metastatic nonseminomatous germ cell cancer is a rare but treatable cancer, we have explored whether there is an association between the experience of the treating institution with this disease and the long-term clinical outcome of the patients, particularly patients with a poor prognosis. METHODS: We analyzed data on 380 patients treated in one of 49 institutions participating in the European Organization for Research and Treatment of Cancer/Medical Research Council randomized trial of four cycles of bleomycin-etoposide-cisplatin followed by two cycles of etoposide-cisplatin versus three cycles of bleomycin-vincristine-cisplatin followed by three cycles of etoposide-ifosfamide-cisplatin-bleomycin, both treatment regimens given with or without filgrastim (granulocyte colony-stimulating factor). Institutions were divided into four groups based on the total number of patients entered in the trial. The groups were compared by use of the Cox proportional hazards model stratified for treatment with filgrastim and for patient prognosis as defined by the International Germ Cell Consensus Classification Group. With the use of this classification, only 65% of the patients had a poor prognosis. RESULTS: Patients treated in the 26 institutions that entered fewer than five patients into the trial had an overall survival that was statistically significantly worse (two-sided P = .010; hazard ratio = 1.85; 95% confidence interval = 1.16-3.03) than that of patients treated in the 23 institutions that entered five patients or more. Overall survival and failure-free survival were similar among institutions that entered at least five patients. The observed effect may be related to differences in adherence to the chemotherapy protocol and in the frequency and extent of surgery for residual masses, although only the differences in dose intensity achieved statistical significance. CONCLUSIONS: Patients treated in institutions that entered fewer than five patients into the trial appeared to have poorer survival than those treated in institutions that entered a larger number of patients with "poor-prognosis" nonseminoma.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  G. C. Toner Clinical Relevance of "Late" in the Management of Late Relapse After Treatment for a Germ Cell Tumor J. Clin. Oncol., December 1, 2008; 26(34): 5502 - 5503. [Full Text] [PDF]
|
|
|
|
|
|
A. Lorch, C. Kollmannsberger, J. T. Hartmann, B. Metzner, I. G.H. Schmidt-Wolf, W. E. Berdel, F. Weissinger, J. Schleicher, G. Egerer, A. Haas, et al. Single Versus Sequential High-Dose Chemotherapy in Patients With Relapsed or Refractory Germ Cell Tumors: A Prospective Randomized Multicenter Trial of the German Testicular Cancer Study Group J. Clin. Oncol., July 1, 2007; 25(19): 2778 - 2784. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. H. Einhorn Role of the Urologist in Metastatic Testicular Cancer J. Clin. Oncol., March 20, 2007; 25(9): 1024 - 1025. [Full Text] [PDF]
|
|
|
|
|
|
D. J. Vaughn and E. A. Stadtmauer Poor-Prognosis Germ Cell Tumors: We Have Not Yet Crossed the Finish Line J. Clin. Oncol., January 20, 2007; 25(3): 239 - 240. [Full Text] [PDF]
|
|
|
|
|
|
R. de Wit and K. Fizazi Controversies in the Management of Clinical Stage I Testis Cancer J. Clin. Oncol., December 10, 2006; 24(35): 5482 - 5492. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Oldenburg, J. M. Martin, and S. D. Fossa Late Relapses of Germ Cell Malignancies: Incidence, Management, and Prognosis J. Clin. Oncol., December 10, 2006; 24(35): 5503 - 5511. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Kawai, S. Hinotsu, T. Oikawa, N. Sekido, K. Hattori, N. Miyanaga, Y. Hasegawa, H. Kojima, T. Shimazui, and H. Akaza Treatment Outcome of Metastatic Testicular Cancer at a Single Institution in Japan, a Country with Low Incidence of Germ Cell Tumor Jpn. J. Clin. Oncol., November 1, 2006; 36(11): 723 - 730. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Kawai, S. Ando, S. Hinotsu, T. Oikawa, N. Sekido, N. Miyanaga, T. Shimazui, and H. Akaza Completion and Toxicity of Induction Chemotherapy for Metastatic Testicular Cancer: An Updated Evaluation of Japanese Patients Jpn. J. Clin. Oncol., July 1, 2006; 36(7): 425 - 431. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Pentheroudakis and N. Pavlidis Juvenile cancer: improving care for adolescents and young adults within the frame of medical oncology Ann. Onc., February 1, 2005; 16(2): 181 - 188. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. C. Toner Early Identification of Therapeutic Failure in Nonseminomatous Germ Cell Tumors by Assessing Serum Tumor Marker Decline During Chemotherapy: Still Not Ready for Routine Clinical Use J. Clin. Oncol., October 1, 2004; 22(19): 3842 - 3845. [Full Text] [PDF]
|
|
|
|
|
|
H. J. Schmoll, R. Souchon, S. Krege, P. Albers, J. Beyer, C. Kollmannsberger, S. D. Fossa, N. E. Skakkebaek, R. de Wit, K. Fizazi, et al. European consensus on diagnosis and treatment of germ cell cancer: a report of the European Germ Cell Cancer Consensus Group (EGCCCG) Ann. Onc., September 1, 2004; 15(9): 1377 - 1399. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Vardy and I. F. Tannock Quality of cancer care Ann. Onc., July 1, 2004; 15(7): 1001 - 1006. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. L de Lemos and R. K O'Brien Development of a pharmacist-coordinated system of chemotherapy protocols in an integrated healthcare delivery organization Journal of Oncology Pharmacy Practice, June 1, 2002; 8(2-3): 39 - 48. [Abstract] [PDF]
|
|
|
|
|
|
J. Beyer, S. Stenning, A. Gerl, S. Fossa, and W. Siegert High-dose versus conventional-dose chemotherapy as first-salvage treatment in patients with non-seminomatous germ-cell tumors: a matched-pair analysis Ann. Onc., April 1, 2002; 13(4): 599 - 605. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. E. Hillner, T. J. Smith, and C. E. Desch Hospital and Physician Volume or Specialization and Outcomes in Cancer Treatment: Importance in Quality of Cancer Care J. Clin. Oncol., June 11, 2000; 18(11): 2327 - 2340. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. J. Feuer, J. Sheinfeld, and G. J. Bosl Does Size Matter? Association Between Number of Patients Treated and Patient Outcome in Metastatic Testicular Cancer J Natl Cancer Inst, May 19, 1999; 91(10): 816 - 818. [Full Text] [PDF]
|
|